MX2023008406A - Formulacion farmaceutica. - Google Patents

Formulacion farmaceutica.

Info

Publication number
MX2023008406A
MX2023008406A MX2023008406A MX2023008406A MX2023008406A MX 2023008406 A MX2023008406 A MX 2023008406A MX 2023008406 A MX2023008406 A MX 2023008406A MX 2023008406 A MX2023008406 A MX 2023008406A MX 2023008406 A MX2023008406 A MX 2023008406A
Authority
MX
Mexico
Prior art keywords
pharmaceutical formulation
preparing
pharmaceutical
relates
pharmaceutical formulations
Prior art date
Application number
MX2023008406A
Other languages
English (en)
Spanish (es)
Inventor
Richard Armer
Matas Marcel De
Original Assignee
Redx Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Redx Pharma Plc filed Critical Redx Pharma Plc
Publication of MX2023008406A publication Critical patent/MX2023008406A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • A61K9/4825Proteins, e.g. gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833Encapsulating processes; Filling of capsules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2023008406A 2021-01-15 2022-01-14 Formulacion farmaceutica. MX2023008406A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2100526.9A GB202100526D0 (en) 2021-01-15 2021-01-15 Pharmaceutical formulation
PCT/GB2022/050083 WO2022153062A1 (en) 2021-01-15 2022-01-14 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
MX2023008406A true MX2023008406A (es) 2023-08-03

Family

ID=74678956

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008406A MX2023008406A (es) 2021-01-15 2022-01-14 Formulacion farmaceutica.

Country Status (10)

Country Link
US (1) US20240082244A1 (https=)
EP (1) EP4277606A1 (https=)
JP (1) JP2024505630A (https=)
KR (1) KR20230133285A (https=)
CN (1) CN116710077A (https=)
AU (1) AU2022208241A1 (https=)
CA (1) CA3202029A1 (https=)
GB (1) GB202100526D0 (https=)
MX (1) MX2023008406A (https=)
WO (1) WO2022153062A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220023266A1 (en) 2018-12-07 2022-01-27 Neurocrine Biosciences, Inc. Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
JP7623365B2 (ja) 2019-09-27 2025-01-28 ニューロクライン バイオサイエンシーズ,インコーポレイテッド Crf受容体アンタゴニストおよび使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA845180B (en) * 1983-07-07 1986-02-26 American Home Prod Pharmaceutical composition containing a liquid lubricant
US9783550B2 (en) * 2013-05-14 2017-10-10 The Board Of Regents Of The University Of Texas System Highly potent inhibitors of porcupine
KR102525131B1 (ko) * 2014-10-08 2023-04-24 레드엑스 파마 피엘씨 Wnt 신호 경로의 억제제로서의 N-피리디닐 아세트아미드 유도체
CN111971063A (zh) * 2018-04-06 2020-11-20 4阵营疗法公司 通过靶向调节基因信号传导网络治疗疾病

Also Published As

Publication number Publication date
AU2022208241A9 (en) 2025-01-09
JP2024505630A (ja) 2024-02-07
GB202100526D0 (en) 2021-03-03
EP4277606A1 (en) 2023-11-22
AU2022208241A1 (en) 2023-07-06
US20240082244A1 (en) 2024-03-14
CN116710077A (zh) 2023-09-05
CA3202029A1 (en) 2022-07-21
WO2022153062A1 (en) 2022-07-21
KR20230133285A (ko) 2023-09-19

Similar Documents

Publication Publication Date Title
MX2023013194A (es) Compuesto inhibidor de atr que contiene sulfoximina.
MX2023012725A (es) Compuestos de 2-aminobenzotiazol y metodos de uso de los mismos.
UY39296A (es) Azaquinolonas sustituidas inhibidoras de parp y composiciones farmacéuticas que las contienen
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
CL2019003610A1 (es) Un esteroide 19 nor-c21-n-pirazolilo c3,3-disustituido cristalino. (divisional solicitud 201900477).
SV2007002427A (es) Una formulacion solida de dosificacion farmaceutica
HN2012001162A (es) Triazolopiridinas
MX2024014861A (es) Inhibidor de la prmt5 de tres anillos fusionados que contiene nitrogeno, y metodo de preparacion del mismo y uso farmaceutico del mismo
MX2018015709A (es) Derivados de azabencimidazol como inhibidores de pi3k beta.
MX2023008406A (es) Formulacion farmaceutica.
MX2023006504A (es) Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo.
MX2025011559A (es) Rendimiento mejorado de formulaciones solidas amorfas y solubilizadas para lograr concentraciones plasmaticas terapeuticas
MX2023002117A (es) Forma amorfa de un inhibidor de malt1 y formulaciones de este.
MX2018008772A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
MX2015016971A (es) Formulacion que comprende un agente hipolipidemico.
CO6321158A2 (es) Formulacion oral
DOP2022000035A (es) Composiciones que comprenden tigolaner para el control de parásitos
ZA202210629B (en) Pharmaceutical composition comprising benzimidazole derivative compound
MX2025006915A (es) Preparación farmacéutica de un compuesto de imidazolinona, método de preparación y uso de esta
MX2024011130A (es) Inhibidor de derivados heterociclicos que contienen nitrogeno, metodo de preparacion y utilizacion del mismo
MX2021002260A (es) Compuestos utiles como moduladores de la autofagia mediada por chaperonas.
CL2024002379A1 (es) Composición farmacéutica y que comprende derivados de difenildiazol métodos de uso
AR112217A1 (es) Una combinación de un inhibidor de mps1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
MX383032B (es) Formulaciones farmaceuticas inyectables de lefamulina.
HN2012001923A (es) Hidrato del hidrocloruro de agomelatina y preparacopn de este